Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: AZN
Latest Price: 3,788.80p  (0.65% Ascending)
52-week High: 4,115.00p
52-week Low: 3,028.50p
Market Cap: 47,787.97M
1 year chart More charts
Deal AZN Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
AstraZeneca
www.astrazeneca.com
Deal AstraZeneca Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.

Pdf

AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

January 21 2013, 12:13pm SocGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant.

SoGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca (LON:AZN).

Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta.

It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently projecting.

However, it sees challenges for Brilinta: “Our forecasts for sales are significantly below consensus because we see multiple hurdles to its use in the US, such as the negative US data from the PLATO study, which deters doctors from prescribing it, an unhelpful twice daily dosing regimen, and an interaction with statins (which is absent in competitors clopidogrel and Effient).”

At midday the shares were changing hands for £30.67, down 9.5p on the day.

 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.